NCT05508906
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05508906
Title Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Olema Pharmaceuticals, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | AUS

Facility Status City State Zip Country Details
Banner MD Anderson Cancer Center Gilbert Arizona 85234 United States Details
University of California San Francisco Health San Francisco California 94158 United States Details
University of Colorado Cancer Center Aurora Colorado 80045 United States Details
Advent Health Hematology and Oncology Orlando Florida 32804 United States Details
University of Iowa Iowa City Iowa 52242 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
Henry Ford Health Detroit Michigan 48126 United States Details
Regents of the University of Minnesota Minneapolis Minnesota 55455 United States Details
Washington University, School of Medicine St Louis Missouri 63110 United States Details
Ichan School of Medicine at Mount Sinai New York New York 10029 United States Details
Atrium Health Levine Cancer Institute Charlotte North Carolina 28204 United States Details
Vanderbilt-Ingram Cancer Center Nashville Tennessee 37232 United States Details
MD Anderson Cancer Center Houston Texas 77030 United States Details
Northwest Medical Specialties Tacoma Washington 98405 United States Details
Macquarie Health Sydney New South Wales 2109 Australia Details
Breast Cancer Research Center- Western Australia Nedlands Western Australia 6009 Australia Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field